Last reviewed · How we verify

NCT07153406: CESAR

Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients

Not yet recruiting Phase 3 Last updated 4 September 2025
What this trial tests

Phase 3 trial testing Experimental regimen in Depressive Disorder in 220 participants. Not yet recruiting.

Timeline
15 September 2025
Primary endpoint
15 September 2026
15 January 2029

Quick facts

Lead sponsorFundación Pública Andaluza para la gestión de la Investigación en Sevilla
PhasePhase 3
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment220
Start date15 September 2025
Primary completion15 September 2026
Estimated completion15 January 2029
Sites9 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — full company profile →

Who can join

Adults 60 to 74, any sex, with Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase III, open label, randomised, multicentre, blind for evaluators clinical trial to evaluate the efficacy of esketamine nasal spray at flexible dosis compared to aripiprazole in elderly participants (\>60 years) who suffer from treatment-resistant major depressive

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Depressive Disorder

Currently open trials in the same condition.

Other Fundación Pública Andaluza para la gestión de la Investigación en Sevilla trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07153406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing